171 related articles for article (PubMed ID: 34773261)
1. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
Maurer M; Giménez-Arnau A; Bernstein JA; Chu CY; Danilycheva I; Hide M; Makris M; Metz M; Savic S; Sitz K; Soong W; Staubach P; Sussman G; Barve A; Burciu A; Hua E; Janocha R; Severin T
Allergy; 2022 Jul; 77(7):2175-2184. PubMed ID: 34773261
[TBL] [Abstract][Full Text] [Related]
2. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
[TBL] [Abstract][Full Text] [Related]
4. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
Staubach P; Alvaro-Lozano M; Sekerel BE; Maurer M; Ben-Shoshan M; Porter M; Hua E; Ji Y; Burciu A; Savelieva M; Severin T; Drollmann A; Bienczak A
Pediatr Allergy Immunol; 2023 Jul; 34(7):e13982. PubMed ID: 37492920
[TBL] [Abstract][Full Text] [Related]
5. Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria.
Giménez-Arnau A; Maurer M; Bernstein J; Staubach P; Barbier N; Hua E; Severin T; Joubert Y; Janocha R; Balp MM
Clin Transl Allergy; 2022 Feb; 12(2):e12121. PubMed ID: 35218324
[TBL] [Abstract][Full Text] [Related]
6. Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria.
Metz M; Bernstein JA; Giménez-Arnau AM; Hide M; Maurer M; Sitz K; Soong W; Sussman G; Hua E; Barve A; Barbier N; Balp MM; Severin T
World Allergy Organ J; 2022 Nov; 15(11):100716. PubMed ID: 36440464
[TBL] [Abstract][Full Text] [Related]
7. Ligelizumab for the treatment of chronic spontaneous urticaria.
Wedi B
Expert Opin Biol Ther; 2020 Aug; 20(8):853-861. PubMed ID: 32380864
[TBL] [Abstract][Full Text] [Related]
8. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
[TBL] [Abstract][Full Text] [Related]
9. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
[TBL] [Abstract][Full Text] [Related]
10. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.
Kuo BS; Li CH; Chen JB; Shiung YY; Chu CY; Lee CH; Liu YJ; Kuo JH; Hsu C; Su HW; Li YF; Lai A; Ho YF; Cheng YN; Huang HX; Lung MC; Wu MS; Yang FH; Lin CH; Tseng W; Yang J; Lin CY; Tsai PH; Chang HK; Wang YJ; Chen T; Lynn S; Liao MJ; Wang CY
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35912861
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
12. Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria.
Muntyanu A; Ouchene L; Ben-Shoshan M; Netchiporouk E
J Cutan Med Surg; 2020; 24(2):201-202. PubMed ID: 32208012
[No Abstract] [Full Text] [Related]
13. Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
Moussa S; Netchiporouk E
Lancet; 2024 Jan; 403(10422):118-119. PubMed ID: 38008108
[No Abstract] [Full Text] [Related]
14. Ligelizumab treatment for severe asthma: learnings from the clinical development programme.
Trischler J; Bottoli I; Janocha R; Heusser C; Jaumont X; Lowe P; Gautier A; Pethe A; Woessner R; Zerwes HG; Zielen S
Clin Transl Immunology; 2021; 10(3):e1255. PubMed ID: 33747510
[TBL] [Abstract][Full Text] [Related]
15. Anti-IgE for the Treatment of Chronic Urticaria.
Wedi B; Traidl S
Immunotargets Ther; 2021; 10():27-45. PubMed ID: 33628747
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
18. New treatments for chronic urticaria.
Kolkhir P; Altrichter S; Munoz M; Hawro T; Maurer M
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):2-12. PubMed ID: 31446134
[TBL] [Abstract][Full Text] [Related]
19. High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?
Türk M; Yılmaz İ
Int Arch Allergy Immunol; 2021; 182(5):461-462. PubMed ID: 33321510
[No Abstract] [Full Text] [Related]
20. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
